retains regular Real Value
of USD80.8 per share. The prevalent price of the corporation is USD67.51. At this time the corporation appears to be under valued
. Macroaxis calculates value of Gilead Sciences
from evaluating the corporation fundamentals
such as Current Valuation
of 6.82B, Return On Asset
of 0.22% and Return On Equity of 0.85% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
Gilead Science took a bad hit when their bet on a medical trial failed. Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead. Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio. For that matter, by any matrix, the stock is cheap and should go higher.
Valuation Drivers Correlation
Net Income Per Employee Enterprise Value Market Capitalization
Selected Gilead Sciences Inc Valuation Data Over Time
Gilead Sciences Total Value Analsys
Gilead Sciences Inc is currently projected to have valuation of 6.82 B with market capitalization of 6.69 B, debt of 595.47 M, and cash on hands of 616.93 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gilead Sciences fundamentals
before making equity appraisal based on the enterprise value of the company
Gilead Sciences Investor Information
of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 10.82. Gilead Sciences Inc last dividend was issued on 2017-03-14. This company had 2:1 split
on January 28, 2013. Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. To learn more about GILEAD SCIENCES call John Martin at 650 574-3000 or check out www.gilead.com.
Gilead Sciences Asset Utilization
Gilead Sciences harnesses its working resources almost 0.22 (percent), generating USD0.0022 for each dollar of working resources held by the corporation. An expanding assets utilization attests that the company is being more effective with each dollar of working resources it retains. In other words assets utilization of Gilead Sciences shows how effective it operates for each dollar spent on its working resources
Gilead Sciences Ownership Allocation (%)
Gilead Sciences secures a total of 1.56 Billion outstanding shares. Majority of Gilead Sciences outstanding shares
are owned by outside corporations
. These institutional investers are referred to non-private investors that are looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to different set of regulations than regular investors in Gilead Sciences Inc. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of how profitable the company is, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns from it at some point.
Gilead Sciences Profitability Analysis
The company reported previous year revenue of 466.79 M. Net Income
was 72.1 M with profit before overhead, payroll, taxes, and interest of 397.07 M.